Zenas Biopharma (ZBIO) Competitors $12.11 +0.17 (+1.42%) As of 06/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ZBIO vs. MNKD, CLDX, INVA, DVAX, NVAX, OPK, GERN, RGLS, MYGN, and RIGLShould you be buying Zenas Biopharma stock or one of its competitors? The main competitors of Zenas Biopharma include MannKind (MNKD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry. Zenas Biopharma vs. Its Competitors MannKind Celldex Therapeutics Innoviva Dynavax Technologies Novavax OPKO Health Geron Regulus Therapeutics Myriad Genetics Rigel Pharmaceuticals MannKind (NASDAQ:MNKD) and Zenas Biopharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability. Does the MarketBeat Community believe in MNKD or ZBIO? MannKind received 585 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 60.35% of users gave MannKind an outperform vote. CompanyUnderperformOutperformMannKindOutperform Votes58960.35% Underperform Votes38739.65% Zenas BiopharmaOutperform Votes4100.00% Underperform VotesNo Votes Does the media refer more to MNKD or ZBIO? In the previous week, Zenas Biopharma had 5 more articles in the media than MannKind. MarketBeat recorded 22 mentions for Zenas Biopharma and 17 mentions for MannKind. MannKind's average media sentiment score of 0.56 beat Zenas Biopharma's score of -0.01 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Zenas Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in MNKD or ZBIO? 49.5% of MannKind shares are owned by institutional investors. 2.7% of MannKind shares are owned by company insiders. Comparatively, 16.5% of Zenas Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend MNKD or ZBIO? MannKind currently has a consensus price target of $10.00, suggesting a potential upside of 157.73%. Zenas Biopharma has a consensus price target of $36.67, suggesting a potential upside of 202.78%. Given Zenas Biopharma's higher possible upside, analysts clearly believe Zenas Biopharma is more favorable than MannKind.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MannKind 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MNKD or ZBIO more profitable? MannKind has a net margin of 8.07% compared to Zenas Biopharma's net margin of 0.00%. Zenas Biopharma's return on equity of 0.00% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets MannKind8.07% -17.74% 8.68% Zenas Biopharma N/A N/A N/A Which has stronger earnings and valuation, MNKD or ZBIO? MannKind has higher revenue and earnings than Zenas Biopharma. Zenas Biopharma is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannKind$297.60M3.96-$11.94M$0.1038.80Zenas Biopharma$15M33.77-$148.51M-$3.55-3.41 SummaryMannKind beats Zenas Biopharma on 12 of the 18 factors compared between the two stocks. Get Zenas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBIO vs. The Competition Export to ExcelMetricZenas BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$506.61M$130.09M$5.57B$8.62BDividend YieldN/A3.74%5.28%4.18%P/E Ratio-3.413.2927.1720.06Price / Sales33.774,336.62410.88157.10Price / CashN/A13.1938.2534.64Price / BookN/A37.537.094.70Net Income-$148.51M-$91.56M$3.23B$247.88M7 Day Performance26.01%2.03%2.91%2.66%1 Month Performance24.33%7.74%9.09%6.40%1 Year PerformanceN/A178.42%31.75%14.07% Zenas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBIOZenas Biopharma1.3302 of 5 stars$12.11+1.4%$36.67+202.8%N/A$506.61M$15M-3.41N/ATrending NewsHigh Trading VolumeMNKDMannKind3.0781 of 5 stars$4.44+3.5%$10.00+125.2%-16.6%$1.35B$297.60M63.43400Trending NewsInsider TradeAnalyst RevisionCLDXCelldex Therapeutics2.9182 of 5 stars$20.00+0.2%$53.90+169.5%-42.6%$1.33B$7.56M-7.78150Positive NewsAnalyst RevisionHigh Trading VolumeINVAInnoviva4.1473 of 5 stars$20.75+3.0%$55.00+165.1%+34.4%$1.30B$369.84M30.07100DVAXDynavax Technologies4.1705 of 5 stars$9.98+1.4%$24.00+140.5%-15.8%$1.20B$294.62M55.44350Positive NewsNVAXNovavax3.8954 of 5 stars$7.32+3.5%$19.00+159.6%-57.6%$1.19B$1.21B-3.241,990Trending NewsOPKOPKO Health4.4952 of 5 stars$1.42+2.5%$2.75+94.3%+2.3%$1.12B$689.41M-7.454,200News CoverageGERNGeron3.1565 of 5 stars$1.58+10.1%$5.06+221.4%-69.7%$1.00B$116.29M-4.9270RGLSRegulus Therapeutics1.7194 of 5 stars$7.99+0.6%$8.50+6.4%+237.5%$553.18MN/A-7.4730Positive NewsMYGNMyriad Genetics4.1021 of 5 stars$4.88+9.4%$14.38+194.8%-76.9%$449.82M$831.30M-3.752,600RIGLRigel Pharmaceuticals3.2834 of 5 stars$20.93+3.9%$36.40+73.9%+107.7%$374.06M$203.08M149.51160Positive NewsAnalyst Revision Related Companies and Tools Related Companies MNKD Alternatives CLDX Alternatives INVA Alternatives DVAX Alternatives NVAX Alternatives OPK Alternatives GERN Alternatives RGLS Alternatives MYGN Alternatives RIGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZBIO) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZBIO Stock Free ZBIO Stock Alerts